Desjarlais John R, Lazar Greg A, Zhukovsky Eugene A, Chu Seung Y
Xencor, Inc. 111 West Lemon Ave., Monrovia, CA 91016, United States.
Drug Discov Today. 2007 Nov;12(21-22):898-910. doi: 10.1016/j.drudis.2007.08.009. Epub 2007 Oct 22.
A unique property of monoclonal antibodies, and a principal reason for their success as cancer therapeutics, is their ability to engage the immune system. A growing set of data supporting the relevance of Fc-mediated effector functions to anti-tumor efficacy has motivated efforts to enhance the interactions between antibodies and Fc receptors expressed on immune cells. Although current approaches have considerable promise for improved clinical performance, the immunobiology of tumors, antibodies, and Fc receptors continues to evolve. In this review we discuss what is known and what is not known about the interactions between therapeutic antibodies and the immune system, with the goal being progress toward clear target profiles for effector engineering efforts.
单克隆抗体的一个独特特性，也是它们作为癌症治疗药物取得成功的主要原因，是它们能够激活免疫系统。越来越多的数据支持Fc介导的效应器功能与抗肿瘤疗效的相关性，这推动了人们努力加强抗体与免疫细胞上表达的Fc受体之间的相互作用。尽管目前的方法在改善临床性能方面有很大前景，但肿瘤、抗体和Fc受体的免疫生物学仍在不断发展。在这篇综述中，我们讨论了关于治疗性抗体与免疫系统之间相互作用已知和未知的内容，目标是朝着明确效应器工程的目标概况取得进展。
